A stronger commitment to patients
Having only been present in the UK medical cannabis market since 2019, Aurora has been able to carve out a niche for itself in the context of recent legalisation. Today, although thousands of patients have the chance to treat themselves with quality medical cannabis, it is still far from being widely available. Indeed, many barriers remain and many patients are unable to obtain it.
Aurora UK & Ireland's Managing Director, Trisha Cassidy, said: "We are committed to helping improve access to medical education for healthcare professionals (...) and we continue to strive to achieve accessibility for all patients prescribed medical cannabis (...)".
The company also advocates for the reimbursement and routine availability of medical
cannabis treatments, including through the NHS.
A new extraction process: quality at its best
The subsidiary has recently developed an innovative extraction process to ensure that the high terpene profile of each product it supplies is maintained. Based on identical flower varieties, this extraction process allows reliable concentrations of active ingredients to be obtained and at the same time ensures the safety and tolerance of the treatment, thanks in particular to consistent terpene profiles.
What is certain is that these new extracts will widen the range of possibilities for UK patients in need of such alternative treatments.